BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 9026938)

  • 21. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
    Urbańska-Ryś H; Robak T
    Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
    Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
    Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG].
    Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K
    Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Beta 2 microglobulin in some hematologic neoplasms].
    Rodríguez MA; Lira P; Foradori A; Grebe G
    Rev Med Chil; 1989 Jun; 116(6):538-42. PubMed ID: 2664940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma].
    Li X; Zhang X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jun; 22(6):303-5. PubMed ID: 11877089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum beta-2-microglobulin in patients with multiple myeloma treated with alpha interferon.
    Murakami H; Ogawara H; Morita K; Saitoh T; Matsushima T; Tamura J; Sawamura M; Karasawa M; Miyawaki S; Schimano S; Satoh S; Tsuchiya J
    J Med; 1997; 28(5-6):311-8. PubMed ID: 9604789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-2-microglobulin in multiple myeloma.
    Musarurwa C; Matarira HT
    Cent Afr J Med; 2004; 50(1-2):19-20. PubMed ID: 15490720
    [No Abstract]   [Full Text] [Related]  

  • 40. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
    Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.